Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 16.02M | 0.00 | 0.00 | 0.00 | 12.06K |
Gross Profit | 16.00M | -4.03M | -134.03K | -227.27K | -188.16K |
EBITDA | 5.75M | -12.35M | -13.55M | -13.73M | -6.65M |
Net Income | 3.59M | -12.51M | -13.58M | -16.39M | -8.09M |
Balance Sheet | |||||
Total Assets | 36.48M | 13.71M | 18.68M | 18.06M | 15.16M |
Cash, Cash Equivalents and Short-Term Investments | 26.79M | 2.45M | 5.96M | 7.85M | 1.19M |
Total Debt | 57.17K | 106.89K | 105.78K | 209.41K | 362.12K |
Total Liabilities | 10.72M | 7.60M | 7.27M | 8.83M | 8.16M |
Stockholders Equity | 25.76M | 6.11M | 11.41M | 9.22M | 7.00M |
Cash Flow | |||||
Free Cash Flow | 8.55M | -9.56M | -10.43M | -10.95M | -7.45M |
Operating Cash Flow | 8.56M | -9.56M | -10.43M | -10.89M | -7.32M |
Investing Cash Flow | -22.66M | 0.00 | 6.38K | -157.02K | -244.44K |
Financing Cash Flow | 15.50M | 5.97M | 8.62M | 17.80M | 5.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | $8.34M | 4.67 | -41.13% | ― | ― | ― | |
52 Neutral | $7.47B | 0.53 | -62.70% | 2.38% | 14.92% | 0.82% | |
― | $8.44M | ― | -302.69% | ― | ― | ― | |
49 Neutral | $9.17M | ― | -451.34% | ― | ― | -57.84% | |
40 Underperform | $8.57M | ― | -64.18% | ― | ― | 1.00% | |
27 Underperform | $9.80M | ― | -342.99% | ― | ― | 99.64% | |
24 Underperform | $8.80M | <0.01 | 13.29% | ― | ― | -261.69% |
Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial of KIO-301 for treating retinitis pigmentosa, aiming to restore vision in patients with severe vision loss. The ABACUS-2 trial will assess the drug’s safety and efficacy across multiple centers in Australia, utilizing a unique photoswitch mechanism that could work for various gene mutations associated with retinal diseases. This innovative approach, supported by Théa Open Innovation, offers hope for a breakthrough in treating inherited retinal conditions.